Over-expression of human cytochrome P450 2J2 activates phase II biotransformation genes that influence anti-cancer drug efficacy [ 2013 - 2015 ]

Also known as: CYP2J2, phase II enzymes and drug resistance in tumours

Research Grant

[Cite as]

Researchers: Prof Michael Murray (Principal investigator) ,  E/Pr Peter Mackenzie

Brief description Increased expression of some enzymes in human tumours contributes to anticancer drug resistance. In many tumours the fatty acid epoxygenase cytochrome P450 2J2 (CYP2J2) is over-expressed. We have found that CYP2J2 activates the expression of phase II enzymes that eliminate anticancer drugs; this is mediated by fatty acid epoxides. In this project we will define the underlying mechanisms of these effects, which may lead to novel strategies to overcome anticancer drug resistance.

Funding Amount $AUD 489,155.47

Funding Scheme Project Grants

Notes Standard Project Grant

Click to explore relationships graph
Viewed: [[ro.stat.viewed]]